Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1301 - 1350 of 1864 results
- Cell-death-inducing monoclonal antibodies raised against DT40 tumor cells: Identification of chicken transferrin receptor as a novel cell-death receptor.
- Integrin alphavbeta6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver.
- Enhanced protein expression by internal ribosomal entry site-driven mRNA translation as a novel approach for in vitro loading of dendritic cells with antigens.
- Differential Sensitivity of A549 Non Small Lung Carcinoma Cell Responses to Epidermal Growth Factor Receptor Pathway Inhibitors.
- Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
- In vivo anti-tumor effect of hybrid vaccine of dendritic cells and esophageal carcinoma cells on esophageal carcinoma cell line 109 in mice with severe combined immune deficiency.
- Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma.
- Phase-I study of Innacell gammadeltatrade mark, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
- Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
- SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
- Synthesis and Biological Activity of Phosphonate Analogues and Geometric Isomers of the Highly Potent Phosphoantigen (E)-1-Hydroxy-2-methylbut-2-enyl 4-Diphosphate.
- Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles.
- A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes.
- Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?
- Anti-tumor immunostimulatory effect of heat-killed tumor cells.
- Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
- Interleukin-2 Promotes Angiogenesis by Activation of Akt and Increase of ROS.
- Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes.
- Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor.
- Sorafenib but not sunitinib affects function of dendritic cells and induction of primary immune responses.
- Chemoprevention of Tumor Metastasis by Liposomal beta-Sitosterol Intake.
- Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes.
- Development of an in vivo antibody-mediated killing (IVAK) model, a flow cytometric method to rapidly evaluate therapeutic antibodies.
- Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival.
- A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy.
- Preclinical safety evaluation of IFNalpha2a-NGR.
- Evaluation of Colon Cancer-Specific Antigen 2 as a Potential Serum Marker for Colorectal Cancer.
- Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study.
- Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.
- Combining the Antigen Processing Components TAP and Tapasin Elicits Enhanced Tumor-Free Survival.
- Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer.
- Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased bax and bak expression.
- Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma.
- Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis.
- Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.
- H-2Kb-restricted CTL epitopes from mouse heparanase elicit an antitumor immune response in vivo.
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer.
- Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
- Anti-idiotypic Immunotherapy in Follicular Lymphoma Patients: Results of a Long Follow-up Study.
- Adenovirus MART-1-engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma.
- Interferon-alpha (IFN-alpha)-conditioned DC Preferentially Stimulate Type-1 and Limit Treg-type In Vitro T-cell Responses From RCC Patients.
- Fc-mOX40L Fusion Protein Produces Complete Remission and Enhanced Survival in 2 Murine Tumor Models.
- A Humanized Tumor Necrosis Factor Receptor 1 (TNFR1)-specific Antagonistic Antibody for Selective Inhibition of Tumor Necrosis Factor (TNF) Action.
- Growth inhibition of insulin-like growth factor I receptor monoclonal antibody to human colorectal cancer cells.
- Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.
- Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.
- Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy.
- Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development.
- Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.
- Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.